Literature DB >> 27617160

Two Novel GLDC Mutations in a Neonate with Nonketotic Hyperglycinemia.

Sarah L Nickerson1, Shanti Balasubramaniam2, Philippa A Dryland1, Jennifer M Love1, Maina P Kava3, Donald R Love1, Debra O Prosser1.   

Abstract

Nonketotic hyperglycinemia, also known as glycine encephalopathy (OMIM #605899), is an autosomal recessive disorder of glycine metabolism resulting from a defect in the glycine cleavage system. We report two novel mutations of the glycine decarboxylase (GLDC) gene observed in a compound heterozygous state in a neonate of mixed Maori and Caucasian parentage: c.395C>T p.(Ser132Leu) in exon 3, and c.256-?_334+?del p.(Ser86Valfs*119), resulting in an out-of-frame deletion of exon 2. Additionally, we describe our experience of implementing the ketogenic diet, alongside standard pharmacological therapy, and highlight its potential therapeutic benefit in severe nonketotic hyperglycinemia, particularly in seizure management.

Entities:  

Keywords:  GLDC gene; glycine decarboxylase; glycine metabolism; ketogenic diet; nonketotic hyperglycinemia

Year:  2016        PMID: 27617160      PMCID: PMC4999328          DOI: 10.1055/s-0036-1584358

Source DB:  PubMed          Journal:  J Pediatr Genet        ISSN: 2146-460X


  33 in total

1.  Prediction of long-term outcome in glycine encephalopathy: a clinical survey.

Authors:  Julia B Hennermann; Jeanne-Marie Berger; Ulrike Grieben; Gunter Scharer; Johan L K Van Hove
Journal:  J Inherit Metab Dis       Date:  2011-10-15       Impact factor: 4.982

Review 2.  The glycine cleavage system: composition, reaction mechanism, and physiological significance.

Authors:  G Kikuchi
Journal:  Mol Cell Biochem       Date:  1973-06-27       Impact factor: 3.396

3.  Assignment of the true and processed genes for human glycine decarboxylase to 9p23-24 and 4q12.

Authors:  M Isobe; H Koyata; T Sakakibara; K Momoi-Isobe; K Hiraga
Journal:  Biochem Biophys Res Commun       Date:  1994-09-30       Impact factor: 3.575

4.  Comprehensive mutation analysis of GLDC, AMT, and GCSH in nonketotic hyperglycinemia.

Authors:  Shigeo Kure; Kumi Kato; Agirios Dinopoulos; Chuck Gail; Ton J DeGrauw; John Christodoulou; Vladimir Bzduch; Rozalia Kalmanchey; Gyorgy Fekete; Alex Trojovsky; Barbara Plecko; Galen Breningstall; Jun Tohyama; Yoko Aoki; Yoichi Matsubara
Journal:  Hum Mutat       Date:  2006-04       Impact factor: 4.878

5.  Natural history of nonketotic hyperglycinemia in 65 patients.

Authors:  J E Hoover-Fong; S Shah; J L K Van Hove; D Applegarth; J Toone; A Hamosh
Journal:  Neurology       Date:  2004-11-23       Impact factor: 9.910

Review 6.  Gene dosage methods as diagnostic tools for the identification of chromosome abnormalities.

Authors:  L Gouas; C Goumy; L Véronèse; A Tchirkov; P Vago
Journal:  Pathol Biol (Paris)       Date:  2008-06-02

7.  Late-onset nonketotic hyperglycinemia with leukodystrophy and an unusual clinical course.

Authors:  Mary Anne Chiong; Peter Procopis; Kevin Carpenter; Bridget Wilcken
Journal:  Pediatr Neurol       Date:  2007-10       Impact factor: 3.372

Review 8.  Clinical, ethical and legal considerations in the treatment of newborns with non-ketotic hyperglycinaemia.

Authors:  A Boneh; S Allan; D Mendelson; M Spriggs; L H Gillam; S H Korman
Journal:  Mol Genet Metab       Date:  2008-04-18       Impact factor: 4.797

9.  Poor outcome for neonatal-type nonketotic hyperglycinemia treated with high-dose sodium benzoate and dextromethorphan.

Authors:  Yin-Hsiu Chien; Chia-Chi Hsu; Aichu Huang; Shi-Ping Chou; Frank-Li Lu; Wang-Tso Lee; Wuh-Liang Hwu
Journal:  J Child Neurol       Date:  2004-01       Impact factor: 1.987

Review 10.  Drug treatment of inborn errors of metabolism: a systematic review.

Authors:  Majid Alfadhel; Khalid Al-Thihli; Hiba Moubayed; Wafaa Eyaid; Majed Al-Jeraisy
Journal:  Arch Dis Child       Date:  2013-03-26       Impact factor: 3.791

View more
  1 in total

Review 1.  Nonketotic Hyperglycinemia: Insight into Current Therapies.

Authors:  Magdalena Nowak; Piotr Chuchra; Justyna Paprocka
Journal:  J Clin Med       Date:  2022-05-27       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.